683 Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

683 Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.1M	Sell	250,000 -80,000	-24%	-$1.72M	0.52%	42
2025 Q4	$8.29M	Buy	330,000 +42,000	+15%	+$985K	0.36%	55
2025 Q3	$6.52M	Sell	288,000 -122,000	-30%	-$2.85M	0.34%	61
2025 Q2	$7.1M	Buy	410,000 +77,000	+23%	+$1.43M	0.47%	56
2025 Q1	$7.28M	Sell	333,000 -27,000	-8%	-$746K	0.5%	57
2024 Q4	$11.5M	Buy	360,000 +125,000	+53%	+$3.76M	0.71%	35
2024 Q3	$6.78M	Buy	235,000 +49,000	+26%	+$1.81M	0.52%	52
2024 Q2	$7.13M	Sell	186,000 -29,000	-13%	-$1.31M	0.54%	49
2024 Q1	$12.6M	Buy	215,000 +85,000	+65%	+$5.42M	0.92%	37
2023 Q4	$7.78M	Sell	130,000 -110,000	-46%	-$5.58M	0.64%	53
2023 Q3	$9.13M	Buy	240,000 +195,700	+442%	+$8.6M	0.71%	50
2023 Q2	$4.04M	Sell	44,300 -115,700	-72%	-$9.98M	0.29%	76
2023 Q1	$10.6M	Sell	160,000 -15,000	-9%	-$866K	0.79%	36
2022 Q4	$9.05M	Buy	+175,000	New	+$9.28M	0.77%	41

Other funds holding APLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

683 Capital Management's APLS Position: Q1 2026 in Review

683 Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 24% in Q1 2026, selling an estimated $1.72M and leaving 250,000 shares worth $10.1M. The position accounts for 0.52% of the portfolio, ranked #42.

683 Capital Management first reported a position in APLS in Q4 2022 and has held it in 14 quarters since. The position peaked at $12.6M in Q1 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

683 Capital Management held 250,000 shares of Apellis Pharmaceuticals worth $10.1M as of Q1 2026.
683 Capital Management sold 80,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $1.72M.
Apellis Pharmaceuticals made up 0.52% of 683 Capital Management's portfolio in Q1 2026, its #42 holding.
683 Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
683 Capital Management's Apellis Pharmaceuticals position peaked at $12.6M in Q1 2024.
323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.